Influence of CD47 expression regulated by PI3K/AKT pathway on the tumor invasiveness of glioblastoma
-
摘要: 目的 探讨通过磷脂酰肌醇3-激酶(PI3K)/蛋白质丝氨酸苏氨酸激酶(AKT)通路调节胶质母细胞瘤CD47表达对肿瘤侵袭性的影响。 方法 选取手术切除并经病理证实的30例胶质母细胞瘤脑组织标本以及10个正常脑组织对照标本。分析低表达及高表达的CD47对胶质母细胞瘤侵袭性的影响。 结果 CD47在胶质母细胞瘤细胞中高表达, CD47低表达显著抑制了肿瘤侵袭性,而CD47的高表达则显著促进肿瘤侵袭性。CD47通过激活PI3K/AKT途径而显著增强胶质母细胞瘤的侵袭性(P<0.05)。 结论 CD47在胶质母细胞瘤细胞中高表达, CD47通过激活PI3K/AKT途径而增强胶质母细胞瘤的侵袭性。
-
关键词:
- 胶质母细胞瘤 /
- CD47 /
- 肿瘤侵袭性 /
- 磷脂酰肌醇3-激酶 /
- 蛋白质丝氨酸苏氨酸激酶
Abstract: Objective To investigate the effect of CD47 expression regulated by phosphatidylinositol 3-kinase(PI3K)/protein serine threonine kinase(AKT)pathway on the tumor invasiveness of glioblastoma. Methods Thirty samples of glioblastoma brain tissue confirmed by pathology were collected, and 10 normal samples of brain tissues were collected as controls. Effect of low and high expressions of CD47 on the invasiveness of glioblastoma were analyzed. Results CD47 was highly expressed in glioblastoma cells, and low expression of CD47 could significantly inhibit the tumor invasiveness, and high expression of CD47 could significantly promote the tumor invasiveness. CD47 was able to significantly enhance invasiveness of glioblastoma by activating the PI3K/AKT pathway(P<0.05). Conclusion CD47 is highly expressed in glioblastoma cells, and CD47 can significantly enhance invasiveness of glioblastoma by activating the PI3K/AKT pathway. -
-
Munshi A. Central nervous system tumors: Spotlight on India[J]. South Asian J Cancer, 2016, 5(3): 146-147.
Xu Y M, Yuan J, Zhang Z H, et al. Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis[J]. Mol Biol Rep, 2012, 39(9): 8979-8985.
Miller T E, Liau B B, Wallace L C, et al. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma[J]. Nature, 2017, 547(7663): 355-359.
Baccelli I, Stenzinger A, Vogel V, et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients[J]. Oncotarget, 2014, 5(18): 8147-8160.
Sun K, Ye L, Liu X P, et al. Expression of CRT and CD47 in Gastric Carcinoma and Their Significanc[J]. Cancer Res Prev Treat, 2019, 46(1): 45-49.
Chao M P, Alizadeh A A, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia[J]. Cancer Res, 2011, 71(4): 1374-1384.
Zhang H M, Lu H Q, Xiang L S, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells[J]. Proc Natl Acad Sci USA, 2015, 112(45): E6215-E6223.
Parida S, Pal I, Parekh A, et al. GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling[J]. Cell Death Dis, 2016, 7: e2154-e2159.
Lee T K, Cheung V C, Lu P, et al. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma[J]. Hepatology, 2014, 60(1): 179-191.
Zhao H, Wang J X, Kong X D, et al. CD47 promotes tumor invasion and metastasis in non-small cell lung cancer[J]. Sci Rep, 2016, 6: 29719-29723.
Lo J, Lau E Y, So F T, et al. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma[J]. Liver Int, 2016, 36(5): 737-745.
Song X S, Shi B, Huang K X, et al. MiR-133a inhibits cervical cancer growth by targeting EGFR[J]. Oncol Rep, 2015, 34(3): 1573-1580.
Prasad S B, Yadav S S, Das M, et al. PI3K/AKT pathway-mediated regulation of p27(Kip1)is associated with cell cycle arrest and apoptosis in cervical cancer[J]. Cell Oncol(Dordr), 2015, 38(3): 215-225.
Chao M P, Tang C, Pachynski R K, et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy[J]. Blood, 2011, 118(18): 4890-4901.
Zhao X W, van Beek E M, Schornagel K, et al. CD47-signal regulatory protein-α(SIRPα)interactions form a barrier for antibody-mediated tumor cell destruction[J]. Proc Natl Acad Sci USA, 2011, 108(45): 18342-18347.
Cioffi M, Trabulo S, Hidalgo M, et al. Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms[J]. Clin Cancer Res, 2015, 21(10): 2325-2337.
Xiao Z Y, Chung H, Banan B, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma[J]. Cancer Lett, 2015, 360(2): 302-309.
Baccelli I, Stenzinger A, Vogel V, et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients[J]. Oncotarget, 2014, 5(18): 8147-8160.
Wang Y H, Xu Z H, Guo S T, et al. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis[J]. Mol Ther, 2013, 21(10): 1919-1929.
Ju B H, Huang Y T, Tian J, et al. In vitro application of anti-CD47 monoclonal antibody for targeted therapy of ovarian cancer[J]. Chinese Journal of Clinical Oncology, 2013, 40(8): 440-443.
Xu J F, Pan X H, Zhang S J, et al. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models[J]. Oncotarget, 2015, 6(27): 23662-23670.
Murata T, Ohnishi H, Okazawa H, et al. CD47 promotes neuronal development through Src- and FRG/Vav2-mediated activation of Rac and Cdc42[J]. J Neurosci, 2006, 26(48): 12397-12407.
Soto-Pantoja D R, Miller T W, Pendrak M L, et al. CD47 deficiency confers cell and tissue radioprotection by activation of autophagy[J]. Autophagy, 2012, 8(11): 1628-1642.
Chao M P, Tang C, Pachynski R K, et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy[J]. Blood, 2011, 118(18): 4890-4901.
Chao M P, Weissman I L, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications[J]. Curr Opin Immunol, 2012, 24(2): 225-232.
Horrigan S K, Reproducibility Project: Cancer Biology. Replication Study: The CD47-signal regulatory protein alpha(SIRPa)interaction is a therapeutic target for human solid tumors[J]. Elife, 2017, 6: e18173-e18183.
Pan Y, Volkmer J P, Mach K E, et al. Endoscopic molecular imaging of human bladder cancer using a CD47 antibody[J]. Sci Transl Med, 2014, 6(260): 148-159.
Ma Y J, Lu C, Li C F, et al. Overexpression of HSPA12B protects against cerebral ischemia/reperfusion injury via a PI3K/Akt-dependent mechanism[J]. Biochim Biophys Acta, 2013, 1832(1): 57-66.
Dong H Q, Zhang X, Dai X N, et al. Lithium ameliorates lipopolysaccharide-induced microglial activation via inhibition of toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1 pathway[J]. J Neuroinflammation, 2014, 11: 140-148.
Li X H, Huang J, Yuan D M, et al. HSPA12B regulates SSeCKS-mediated astrocyte inflammatory activation in neuroinflammation[J]. Exp Cell Res, 2015, 339(2): 310-319.
Cheaib B, Auguste A, Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges[J]. Chin J Cancer, 2015, 34(1): 4-16.
-
期刊类型引用(39)
1. 刘琚. 危重症专职护理对慢阻肺患者血气指标及呼吸功能的影响. 医学信息. 2024(13): 146-149 . 
百度学术
2. 华辉，王进静，夏彩霞. 专职护理小组结合精细化护理在BiPAP呼吸机治疗慢阻肺急性加重期合并呼吸衰竭患者中的应用. 包头医学院学报. 2024(10): 78-81+96 . 百度学术
3. 张静，万黎. 危重症专职护理小组对重症慢性阻塞性肺疾病患者预后的影响. 吉林医学. 2023(03): 792-795 . 百度学术
4. 曹洁，程熙敏，祝晓志. 早期护理干预应用于呼吸衰竭重症监护患者的价值和意义. 黑龙江医学. 2023(15): 1898-1900 . 百度学术
5. 阮春燕，耿金花，邬欣桃，林俏丽. 中医护理干预对COPD急性加重期患者心理状态及生活质量的影响. 临床医学工程. 2022(08): 1123-1124 . 百度学术
6. 王惠群，王春艳，张培. 观察一体化护理模式对ICU呼吸衰竭患者睡眠质量及心理状态的影响. 世界睡眠医学杂志. 2022(07): 1351-1353 . 百度学术
7. 龚文娟. 基于多学科干预的动机性访谈在COPD患者中的应用价值分析. 现代诊断与治疗. 2022(16): 2520-2523 . 百度学术
8. 胡招娣. 机械排痰仪联合精细化护理在慢性阻塞性肺疾病急性加重期患者中的应用. 医疗装备. 2021(04): 157-158 . 百度学术
9. 潘湘玲. 优质护理干预在重症慢性阻塞性肺疾病合并呼吸衰竭患者中的应用研究. 临床研究. 2021(05): 166-167 . 百度学术
10. 赵洁敏，左万里，黄志贞. 抗血小板治疗对高龄COPD急性加重期患者疗效及TNF-α、hs-CRP水平的影响. 航空航天医学杂志. 2021(05): 545-547 . 百度学术
11. 张巍，朱娅丽，陈济超，纪红. 老年COPD急性加重期合并呼吸衰竭患者营养不良的危险因素分析及量化预测模型的建立. 医学综述. 2021(11): 2249-2253+2259 . 百度学术
12. 刘绍燕，王琳，卢家宜，黎松娇. 早期肺康复训练对慢性阻塞性肺疾病急性加重期行无创机械通气患者的影响. 齐鲁护理杂志. 2021(15): 91-94 . 百度学术
13. 吴晓倩，孙茜，宋素萍. 人性化护理模式在老年呼吸衰竭患者中的应用. 中国全科医学. 2021(S1): 210-212 . 百度学术
14. 王菊芬，刘胜岗，龙静，杨红忠. 高流量氧疗联合纳洛酮治疗老年重症呼吸衰竭的临床疗效及其对血气指标的影响. 临床合理用药杂志. 2021(24): 59-61 . 百度学术
15. 刘娜. 整体护理干预在慢性阻塞性肺疾病合并呼吸衰竭患者中的效果研究. 中国医药指南. 2021(22): 138-139 . 百度学术
16. 熊益，董智强. 优质护理干预对老年慢性阻塞性肺疾病急性加重期并发呼吸衰竭患者肺功能及血气指标的影响. 山西医药杂志. 2021(18): 2723-2726 . 百度学术
17. 王建梅. 分析优质护理在老年慢阻肺患者护理中的应用效果及满意度影响. 黑龙江中医药. 2021(04): 371-372 . 百度学术
18. 韩慧娟，高东亚，李利华. 精细化照护对慢性阻塞性肺疾病急性加重期患者肺功能和生存质量的影响. 护理实践与研究. 2021(22): 3394-3396 . 百度学术
19. 郭秀敏. 精细化护理对AECOPD伴呼吸衰竭患者呼吸机耐受情况的影响. 黑龙江中医药. 2021(06): 289-290 . 百度学术
20. 王平. 优质干预模式对慢性阻塞性肺疾病急性加重期并发呼吸衰竭患者治疗效果及家属疾病不确定感的影响. 中国健康心理学杂志. 2020(01): 21-25 . 百度学术
21. 程柚圆. 优质护理在无创呼吸机治疗呼吸衰竭患者中的应用. 医疗装备. 2020(09): 174-176 . 百度学术
22. 徐婉贞. 优质护理干预对老年支气管哮喘患者负性情绪的影响. 首都食品与医药. 2020(12): 183 . 百度学术
23. 何志雄，汤渝玲. 慢性阻塞性肺疾病并发急性呼吸衰竭的危险因素分析. 中国社区医师. 2020(24): 34-35 . 百度学术
24. 朱海艳，王晓斐，陈海兰，朱敏，曹蓉蓉. 护理干预对老年慢性阻塞性肺疾病患者康复依从性的影响. 中外医疗. 2020(19): 132-134 . 百度学术
25. 郭瑾洁，孙广荣，王明明. 基于跌倒风险评估策略下的针对性护理在营养不良COPD恢复期患者中的应用. 齐鲁护理杂志. 2020(19): 78-80 . 百度学术
26. 王艳红，虞意华. 精细化护理在慢性阻塞性肺疾病急性加重期合并2型呼吸衰竭患者中的应用. 中华全科医学. 2019(02): 321-324 . 百度学术
27. 关丽清，冯树开，关贞妹，彭秋莲，李海英. 慢性阻塞性肺疾病并发多器官功能衰竭患者的护理干预. 中国医药科学. 2019(04): 146-149 . 百度学术
28. 杨晓珍. 优质护理干预对老年慢性阻塞性肺疾病急性加重期并发呼吸衰竭患者的应用研究. 中国医药指南. 2019(08): 267 . 百度学术
29. 张丽. 优质护理在老年慢性阻塞性肺疾病护理中的应用效果. 人人健康. 2019(09): 121 . 百度学术
30. 刘红云，张晓娜. 早期护理干预对呼吸衰竭重症监护患者临床指标及并发症的影响. 黑龙江医学. 2019(04): 407-409 . 百度学术
31. 邹柳. 慢性阻塞性肺气肿患者护理中综合优质护理的运用评估. 中国医药指南. 2019(10): 264-265 . 百度学术
32. 杜国菊，左娇娇，刘彬彬. 总结优质护理服务在老年慢性阻塞性肺疾病患者中的实施效果与体会. 当代医学. 2019(20): 179-181 . 百度学术
33. 胡四菊. 综合护理对慢性阻塞性肺疾病急性加重期患者肺功能与临床症状的影响. 中国医学创新. 2019(25): 87-90 . 百度学术
34. 黄慧. 慢性阻塞性肺疾病并发气胸的护理体会. 中国社区医师. 2019(25): 144-145 . 百度学术
35. 益西卓玛，次仁卓玛. 西藏地区慢性阻塞性肺疾病并呼吸衰竭的护理措施及效果. 世界最新医学信息文摘. 2019(91): 291-292 . 百度学术
36. 陈展. 老年慢性阻塞性肺气肿并发自发性气胸的护理分析. 心理月刊. 2019(23): 121 . 百度学术
37. 庞蕊楠. 探讨优质护理对重症慢性阻塞性肺疾病合并呼吸衰竭治疗效果的影响. 世界最新医学信息文摘. 2019(A5): 267-268 . 百度学术
38. 何小路，黄梅，张莉. 优质护理在急诊呼吸衰竭行无创呼吸机治疗患者中的应用. 医疗装备. 2019(23): 187-189 . 百度学术
39. 吴雪玲，吉小玲，杜乃婷. 以人文关怀为主的优质护理干预在COPD合并呼吸衰竭患者中的应用. 临床医药文献电子杂志. 2019(90): 119+121 . 百度学术
其他类型引用(1)
计量
- 文章访问数: 303
- HTML全文浏览量: 83
- PDF下载量: 13
- 被引次数: 40
下载:
苏公网安备 32100302010246号